Basestone Pharmaceuticals (02616.HK) announced that the long-term treatment and survival data of cetuximab (trade name Zeltrap) combined with platinum-containing chemotherapy GEMSTONE-302 study has been released at the 2024 European Society for Medical Oncology (ESMO) annual meeting.

The company stated that cetuximab is the first and only PD-L1 monoclonal antibody to publish long-term survival data for first-line treatment of squamous and non-squamous non-small cell lung cancer (NSCLC) combined with platinum-containing chemotherapy. Four-year follow-up data showed that compared to placebo combined with platinum-containing chemotherapy, cetuximab combined with platinum-containing chemotherapy consistently demonstrated superior progression-free survival (PFS) and overall survival (OS) benefits, with four-year survival rates of 32.1% and 17.3% respectively.

In addition, patients who received at least two years of cetuximab treatment achieved persistent tumor relief and impressive four-year overall survival rates, demonstrating the long-term treatment effect of cetuximab in improving patient survival. For patients with baseline brain metastases, cetuximab combined with platinum-containing chemotherapy extended PFS and OS compared to placebo combined with platinum-containing chemotherapy, with median OS of 26 months and 9 months respectively.